Isolation and Assessment of Blood-Circulating Cancer Exosomes with LSS and SERS Lab on a Chip Optical Spectroscopic Instrument

使用芯片光学光谱仪器上的 LSS 和 SERS 实验室分离和评估血液循环癌症外泌体

• 批准号: 10084275
• 负责人: Lev T Perelman
• 金额: $ 65.53万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-02-01 至 2023-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10084275
• 关键词: Address; Adopted; Algorithms; Apoptotic; Area; Biochemical; Biogenesis; Biological; Biomedical Engineering; Blood; Blood Circulation; Blood specimen; Cancer Biology; Cancer Center; Cancerous; Cell Culture Techniques; Cells; Cellular biology; Clinical; Clinical Data; Clinical Management; Clinical Research; Collaborations; DNA; Data; Development; Diagnosis; Doctor of Philosophy; Endocytic Vesicle; Endoscopy; Epithelial; Gastroenterologist; Gastrointestinal tract structure; Goals; Human; Imaging Device; Indiana; Industrialization; Lab-On-A-Chips; Laboratories; Light; Light-Scattering Spectroscopy; Liquid substance; Malignant Neoplasms; Malignant neoplasm of pancreas; Mathematics; Measurement; Measures; Medicine; Membrane; Messenger RNA; Methodology; Methods; MicroRNAs; Microfabrication; Microfluidic Microchips; Molecular; Monitor; Nature; Neoplasm Circulating Cells; Neoplasm Metastasis; Normal Cell; Oncogenic; Oncology; Optics; Organ; Organelles; Pathologist; Peripheral; Physiological; Plasma; Primary Neoplasm; Property; Proteins; Raman Spectrum Analysis; Refractive Indices; Research; Sampling; Scientist; Screening for cancer; Shapes; Signal Pathway; Site; Source; Spectrum Analysis; Statistical Data Interpretation; Surface; System; Systems Development; Techniques; Testing; Universities; Vesicle; Vision; algorithm development; angiogenesis; base; cancer cell; cancer genetics; cell free DNA; chemical fingerprinting; clinical application; clinical imaging; decision making algorithm; early detection biomarkers; exosome; experience; improved; insight; instrument; instrumentation; interest; laboratory experiment; light scattering; microvesicles; molecular marker; neoplastic cell; novel; pancreatic cancer patients; physical property; polarized light; predictive marker; response; single molecule; tumor; tumor progression; tumorigenesis; vibration

Project Summary Shed into the peripheral circulation from a primary tumor, circulating tumor cells (CTCs) are limited by their extremely sparse concentrations in blood. In contrast, molecular markers secreted by tumor cells into the vasculature are present in much higher concentrations and could provide important insight on cancer cell biology and predictive biomarkers for early detection, progression and metastasis. These markers, including soluble proteins, cell-free DNA (cfDNA), and circulating microvesicles and exosomes have been shown to contain valuable information on the molecular state of often difficult to access tumor sites. Unfortunately, the source of the soluble proteins found in blood cannot be determined, resulting in the high false-positive rates, while significantly more specific cfDNA often reflect the dying or apoptotic cells. Exosomes, small membrane vesicles of endocytic origin, show the greatest potential as an easily accessible biomarker for early cancer detection and monitoring due to their unique properties, including their stability in biological fluids and their potential to be efficiently isolated. Cancer cells release more exosomes than normal cells and exosomes secreted from tumor cells can promote tumor progression, survival, invasion and angiogenesis. In this application we propose to develop an optical spectroscopic technique, which combines light scattering spectroscopy (LSS) and surface enhanced Raman spectroscopy (SERS) for highly rigorous isolation and assessment of blood-circulating cancer exosomes for early cancer detection in a rapid and inexpensive lab-on-a-chip system. As it is shown in this application, not only LSS can separate exosomes from microvesicles, the capability not available at the moment, but it also can differentiate various types of exosomes originated in different organs of the digestive tract, while SERS is capable of differentiating exosomes secreted by cancerous and normal cells of the same organ.

项目概要 循环肿瘤细胞（CTC）从原发性肿瘤流入外周循环，受到以下因素的限制： 它们在血液中的浓度极其稀少。相比之下，肿瘤细胞分泌的分子标记 进入脉管系统的浓度要高得多，可以提供重要的见解 用于早期检测、进展和转移的癌细胞生物学和预测生物标志物。这些 标记物，包括可溶性蛋白质、游离 DNA (cfDNA) 以及循环微泡和外泌体 已被证明包含有关通常难以获取的肿瘤的分子状态的有价值的信息 网站。不幸的是，血液中可溶性蛋白质的来源无法确定，导致 高假阳性率，而显着更具体的 cfDNA 通常反映死亡或凋亡 细胞。外泌体是一种内吞起源的小膜囊泡，作为一种容易被消化的药物显示出最大的潜力。 由于其独特的特性，可用于早期癌症检测和监测的可访问生物标志物，包括 它们在生物体液中的稳定性以及有效分离的潜力。癌细胞释放更多 外泌体比正常细胞和肿瘤细胞分泌的外泌体更能促进肿瘤进展， 生存、侵袭和血管生成。 在此应用中，我们建议开发一种光学光谱技术，该技术结合了 光散射光谱 (LSS) 和表面增强拉曼光谱 (SERS) 严格分离和评估血液循环癌症外泌体，用于早期癌症检测 快速且廉价的芯片实验室系统。正如本应用所示，不仅 LSS 可以分离 来自微泡的外泌体，目前还没有这种能力，但它也可以区分 各种类型的外泌体起源于消化道的不同器官，而SERS能够 区分同一器官的癌细胞和正常细胞分泌的外泌体。